research use only
Cat.No.S4254
| Related Targets | Integrase Bacterial Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Antibiotics Inhibitors | G418 Sulfate (Geneticin) Puromycin Nanchangmycin Sitafloxacin Hydrate Fusidine Gamithromycin Thiamphenicol Tildipirosin Spiramycin Nadifloxacin |
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 637.66 | Formula | C21H41N5O11.xH2SO4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 65710-07-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Ai3-29795 | Smiles | CNC1C(C2C(CC(C(O2)OC3C(CC(C(C3O)O)N)N)N)OC1OC4C(C(C(C(O4)CO)N)O)O)O.OS(=O)(=O)O | ||
| In vitro |
Apramycin consumption at farm level is most probably driving the increasing occurrence of apramycin/gentamicin cross-resistant [aac(3)-IV positive] E. coli in diseased pigs and healthy finishers at slaughter. Apramycin inhibits A. pleuropneumoniae FMV 87-682 with MIC50 of 8 mg/L. Apramycin (1/4 MIC) in the medium decreases the rate of growth of the bacterial strains tested, and causes the postantibiotic effect (PAE) up to 5 hours. Apramycin significantly reduces the haemolytic activity of A. pleuropneumoniae and affects the capsular material production of this isolate and of one isolate of P. multocida (type A). Apramycin induces translation errors, as assayed by incorporation of leucine, isoleucine and serine, although this effect occurs only to a limited extent, in cell-free systems from Escherichia coli programmed with poly(U). Apramycin inhibits the translocation step of protein synthesis both in vivo, in protoplasts of Bacillus megaterium, and in vitro, in cell-free systems from E. coli.
|
|---|---|
| In vivo |
Apramycin (225 mg/L) totally suppresses mortality and significantly reduces Salmonella excretion in comparison with non-treated chicks.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05590728 | Recruiting | Bacterial Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
June 16 2023 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.